Transgene S.a.

Transgene

Benoît Grellier

Michel Geist

Christine Thioudellet

Jean-Baptiste Marchand

Hélène Haegel

Nathalie Silvestre

Bruce Acres

Kaïdre Bendjama

Hèléne Haegel

Helene Haegel

The present invention generally relates to a personalized cancer vaccine comprising a recombinant poxvirus encoding one or more neopeptide(s) or a composition comprising such a recombinant poxvirus and a pharmaceutically acceptable vehicle as well as the use of the personalized cancer vaccine for treating a cancerous subject in need thereof. A specific embodiment is directed to a method of providing such a vaccine or composition comprising an identification step comprising a) extracting the DNA from a tumor sample and a non-tumor sample, b) selecting target regions, c) sequencing the target regions from the extracted DNAs and d) identifying one or more tumor-specific mutation(s) by comparing the DNA sequences obtained from the tumor and non-tumor samples. Embodiments also include a method of treating cancer or preventing its relapse comprising administration of such a personalized cancer vaccine. The invention is of very special interest in the field of personalized immunotherapy.

Personalized vaccine

The present invention provides antibodies specific for the CSF-1R, compositions comprising said antibodies and methods of treatment using such compositions.

Antibody against the CSF-1R

The present invention concerns biomarkers and use thereof for determining whether a subject is or is not susceptible to developing a prophylactic or therapeutic immune response after such treatment.

Biomarker for treating cancer patients

Growing community of inventors

Strasbourg, France

Benoît Grellier